GNPX · Genprex, Inc.
$1.91
-0.07 (-3.54%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of our recurring losses from operations and the need for additional financing to fund our operating and capital requirements, there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively over the next 12 months, which raises substantial doubt as to our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$1.62M
Shares
819,709
Volume · Oct 23
77.17K
Avg daily vol (3M)
270.31K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.98
Open$1.99
Day$1.98–2.05
52W close$1.98–241.12
Avg vol 30d250K
Short int97K · 11.8% float · 1.0d
Short vol31%
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$16.50M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$15.15M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+21.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
11.8%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 19 · elevated
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−91%
below
Price vs 50-day avg
−39%
below
RSI (14)
24
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−44%
trailing
6-month return
−90%
trailing
YTD return
−95%
this year
Relative strength
−96%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $22 — 200d above 50d
Institutional flow
Accumulating
1 of 27 funds reported for Sep 30 · net +6 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.84% of float · ▲ +17.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
27 holders — mid 3-yr range
Squeeze score
61
elevated · 0–100
Fundamentals
Free cash flow
$-15.3M
Balance sheet
$7.8M
net cash
Quant / Vol
risk profile
Volatility
113%
annualized · 1-yr
Max drawdown
−99%
past year
ATR
12.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−91%
Bearish
Price vs 50-day avg
−39%
Bearish
RSI (14)
24
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $22 — 200d above 50d
Institutional flow
Accumulating
1 of 27 funds reported for Sep 30 · net +6 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.84% of float · ▲ +17.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
27 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $2 · 0%
Range high $241
vs 200-day avg -91%
vs 50-day avg -39%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GNPX
this stock
Genprex, Inc.
|
$1.62M | — | — | — | 11.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.14B | +18.0% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.33B | +6.1% | +20.8% | 20.3 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.90B | +587.1% | +4.3% | — | 7.7% |
|
CSLLY
Csl Ltd
|
$65.88B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 21, 2026
- This year
- 27
Genprex highlighted peer-reviewed mouse research suggesting TUSC2 supports healthy brain aging; TUSC2 expression declined significantly with age in 11 of 13 examined human brain regions.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GNPX | -13.5% | -43.8% | -90.2% | -32.2% | -94.9% |
| SPY | -1.0% | -0.4% | +6.0% | +0.2% | +12.0% |
| vs SPY | -12.5% | -43.3% | -96.2% | -32.4% | -106.9% |